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The anesthetic propofol confers cardioprotection against myocardial ischemia-reperfusion injury (IRI) by reducing reactive oxygen
species (ROS). However, its cardioprotection on patients is inconsistent. Similarly, the beneficial effect of tight glycemic control
during cardiac surgery in patients has recently been questioned. We postulated that low glucose (LG) may promote ROS formation
through enhancing fatty acid (FA) oxidation and unmask propofol cardioprotection during IRI. Rat hearts were isolated and
randomly assigned to be perfused with Krebs-Henseleit solution with glucose at 5.5mM (LG) or 8mM (G) in the absence or
presence of propofol (5𝜇g/mL) or propofol plus trimetazidine (TMZ). Hearts were subjected to 35 minutes of ischemia followed
by 60 minutes of reperfusion. Myocardial infarct size (IS) and cardiac CK-MB were significantly higher in LG than in G group
(P < 0.05), associated with reduced left ventricular developed pressure and increases in postischemic cardiac contracture. Cardiac
15-F2t-isoprostanewas higher, accompaniedwith higher cardiac lipid transporter CD36 protein expression in LG. Propofol reduced
IS, improved cardiac function, and reduced CD36 in G but not in LG. TMZ facilitated propofol cardioprotection in LG.Therefore,
isolated heart with low glucose lost sensitivity to propofol treatment through enhancing FA oxidation and TMZ supplementation
restored the sensitivity to propofol.
1. Introduction
Ischemic heart disease is a major cause of mortality, and the
global incidence is rising rapidly. Essentially it is a reduction
of heart blood flow usually secondary to atherosclerosis
which then reduces the delivery of oxygen and nutrients.
Rupture of vulnerable arterial plaques and subsequent throm-
bosis results in myocardial infarction (MI) and this is one of
the commonest perioperative complications after noncardiac
surgery [1], especially in patients with diabetes [2–4]. In non-
operative settings, reperfusion therapies currently remain the
mainstay therapy for the ischemia results from coronary
occlusion. Reperfusion strategies, such as thrombolysis,
angioplasty, and percutaneous coronary intervention (PCI),
when applied expeditiously, and coronary artery bypass graft-
ing (CABG) can restore coronary flow and limit myocardial
infarct size (IS), and reperfusion per se can paradoxically trig-
ger irreversible tissue injury, namely, ischemia-reperfusion
injury (IRI) which is regarded as an important contributor
to the unsuccessful recovery after reperfusion therapy [5,
6]. The increased reactive oxygen species (ROS) production
during reperfusion and the subsequently increased oxidative
damage are regarded as a pivotal factor contributing to the
pathogenesis of IRI [7, 8].
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To date, a large body of the literature supports the concept
that disturbances in cardiac energy metabolism have been
involved in exaggerating IRI, in contrast to normal heart
where fatty acid and glucose metabolism, specifically fatty
acid (FA) oxidation and glucose oxidation, are tightly regu-
lated [9]. Administering a high level of FA in healthy hearts
can inhibit glucose oxidation and exacerbate IRI [10]. During
ischemia, glucose becomes the preferred cardiac energy sub-
strate, as it requires less oxygen for oxidation than an equi-
molar amount of carbon derived from FA. The metabolic
shift between FA oxidation and glucose oxidation has been
proposed to be the key contributor in the pathogenesis of
impaired cardiac function in ischemic reperfused hearts [11]
and a recent study further demonstrates that the fatty acid
transporter, FAT/CD36, plays critical roles in coordinating
changes in cardiac substratemetabolism during ischemia and
reperfusion [12]. Clinical data shows that patients with diabe-
tes aremore frequently encountered in ischemic heart disease
and more vulnerable to IRI than nondiabetics and hyper-
glycemia-induced oxidative stress may further exacerbate
IRI [13]. In addition, cardiac energy metabolism in diabetic
hearts is altered where glucose utilization is impaired which
causes a switch to predominantly using FA for energy supply
[14]. This metabolic maladaptation, resulting from elevated
plasma free fatty acids, excessive FA accumulation, and incre-
ment of mitochondrial uncoupling and free radical accumu-
lation, will provide feedback to inhibit glucose uptake, which
is detrimental to the ischemic myocardium and amplifies
deleterious effects [10, 15] and might be the fundamental
mechanism governing the increased vulnerability of the
diabetic heart to IRI. In line with this mechanism, switching
the energy supply preference away from FA oxidation and
subsequently to greater glucose oxidation has been reported
to be cardioprotective in lessening myocardial IRI [16].
Accumulating evidence supports that administration of
insulin to maintain blood glucose at a level below 215mg/dL
can improve long-term survival in diabetic patients suffering
from acute myocardial infarction [17–19]. Consistent with
this finding, tight glycemic control with glucose-insulin-
potassium (GIK) solution that normalized serum glucose
concentration from 125 to 200mg/dL has been shown to
significantly decrease the morbidity in diabetic patients
undergoing CABG surgery [16]. Further lowing blood glu-
cose values to no higher than 110mg/dL with intensive
insulin therapy has also been found to be beneficial among
critically ill patients [20]. However, the beneficial effects of
tight glycemic control during cardiac surgery in patients
remain questioned and controversial as conflicting reports
have emerged. In contrast to aforementioned studies, other
researches demonstrated that intensive blood glucose control
has no effect on reducing mortality in patients with type 1
or type 2 diabetes [21] and significantly increased the risk
of intraoperative hypoglycaemia without clear postoperative
benefit in patients undergoing cardiac surgery using car-
diopulmonary [22]. So far, to our knowledge, there is no
direct evidence to explore the effects and mechanism of tight
glycemic control during myocardial IRI.
Propofol, a commonly used intravenous anesthetic,
has antioxidant property, which enhances the capacity of
endogenous cardiac antioxidant to inhibit ROS-mediated
lipid peroxidation [23, 24] and attenuates postischemic
myocardial cellular injury and oxidative stress in patients
undergoing cardiac surgery [25] and in rat hearts subjected
to global myocardial IRI [26]. However, controversy about
propofol cardioprotection persists. For example, propofol
failed to attenuate ROS production during ischemia reper-
fusion in the isolated rat heart [27]. The precise reasons
for different outcomes are as yet unknown. Furthermore, a
study shows that propofol cardioprotection was abrogated
in diabetic condition [28]. However, study regarding the
effectiveness of propofol at different glucose concentrations
in combating myocardial IRI has not been elucidated. In
particular, studies addressing whether or not the cardiopro-
tective effect of propofol is related to FA oxidation and lipid
peroxidation production are lacking. To examine this, we
use low glucose concentration at 5.5mM (which is equal to
100mg/dL) to mimic tight glycemic control condition [20]
and 8mM as normal glucose (which is about the normal
high postmeal glucose level) in isolated ischemic perfused rat
heart model to explore the impact of glucose concentration
on propofol cardioprotection against myocardial IRI, and we
incorporated the use of trimetazidine (TMZ), a partial FA
oxidation inhibitor to explore the effect and mechanism of
inhibiting FAmetabolism in attenuating postischemic oxida-
tive stress and myocardial IRI at varying glucose concentra-
tions and its potential impact on propofol cardioprotection.
2. Materials and Methods
2.1. Experimental Protocol. Hearts were randomly assigned
to one of the six experimental groups (𝑛 = 7 per group):
low glucose concentration at 5.5mM (LG), LG plus propofol
(5 𝜇g/mL) (LG+P), LG plus propofol together with the
partial FA oxidation inhibitor trimetazidine (TMZ) (1𝜇M)
(LG+P+TMZ), glucose concentration at 8mM (G), G plus
propofol (G+P), and G plus propofol together with TMZ
(G+P+TMZ). The propofol concentration of 5𝜇g/mL was
chosen based on our previous finding that propofol used at
this concentration can confer cardioprotection in the isolated
ischemic reperfused rat hearts [26]. After 20 minutes of
stabilization (baseline, BS20), the heart was subjected to
35min global ischemia by turning off the perfusion and
followed by 60min reperfusion using Langendorff-perfused
system. The study drugs propofol and TMZ were perfused
through the aorta via a minipump. The LV pressure signal
was recorded using a PowerLab data acquisition system
and processed to yield left ventricle developed pressure
(LVDP) calculated from left ventricular end-diastolic pres-
sure (LVEDP) and LV peak systolic pressure (LVSP) (LVDP =
LVSP − LVEDP). Coronary perfusion pressure (CPP) was
measured via a side arm of the perfusion cannula connected
to a pressure transducer as described [29]. Effluent samples
during baseline, ischemia, and reperfusion were collected
at different time points for analysis for creatine kinase MB
(CK-MB), endothelin-1 (ET-1), and free 15-F2t-isoprostane
(15-F2t-IsoP) concentration described as below. Heart tissue
protein expression of CD36, a cardiac lipid transporter, was
measured by Western blotting.
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2.2. Global Ischemia by Langendorff-Perfused System in Ex
Vivo. Male Sprague-Dawley rats (250 ± 10 g) were used at
approximately 6 weeks of age from the Laboratory Animal
Service Centres, the University of Hong Kong and Wuhan
University, China. Rats were housed and given free access
to standard food and water according to the principles
of Animal Care of the University of Hong Kong. Exper-
iments were approved by the Committee on Use of Live
Animals in Teaching and Research (CULATR). Rats were
anaesthetized by injection of intraperitoneal pentobarbital
sodium (65mg/kg).Median thoracotomywas performed and
hearts were quickly excised and immersed in ice-cold Krebs-
Henseleit (KH) solution. Hearts were gently squeezed to
remove residual blood to prevent clot formation.Then, hearts
were cannulated via the aorta and perfused as nonworking
“Langendorff” method. The perfusate at a constant flow rate
of 10mL/min which was KH solution that contained (in
mM) NaHCO
3
24, NaCl 118, MgCl
2
1.2, CaCl
2
1.25, KCl
4.63, KH
2
PO
4
1.17, and glucose 5.5 or 8 was previously
equilibrated with a mixture of 95% O
2
− and 5% CO
2
at 37∘C
using a thermostatically controlled water circulating system.
The heart was kept warm in a chamber with circulating
water controlled at 37∘C. A water-filled balloon was then
inserted into the left ventricle through the mitral valve and
connected to a pressure transducer for the determination of
LV pressure. The balloon was inflated to a diastolic pressure
of ∼5–10mmHg.
2.3.Myocardial Infarct Size (IS). At the end of reperfusion, 1%
2,3,5-triphenyl-tetrazolium chloride (TTC) reaction (Sigma
Chemical Co., St. Louis, MO) in phosphate buffer at pH
7.4 was pumped into the heart until the epicardial surface
became deep red. Then tissues were fixed overnight in 10%
formalin. The infarcted areas (white) and viable areas (red)
for each slice were traced and digitized using a computerized
planimetry technique (SigmaScan 4.0, Systat Software Inc.,
Richmond, CA). The ratio of infarct size (white)/total area
(white plus red) was used to compare the differences among
groups.
2.4. Creatine KinaseMB (CK-MB). Cytoplasmic enzymeCK-
MB reversibly catalyzes the reaction fromATP and creatine to
phosphocreatine and ADP. Increased CK-MB concentration
is used as an index of myocardial cell injury. The level of
CK-MB was determined using a commercial ELISA assay
kit (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions as described [30]. Briefly, effluent
perfusate was collected at 20min after baseline stabilization
(BS20) and at 1 (Re-1) and 60 (Re-60) min of reperfusion and
assayed in a 96-well plate precoated with antibody specific to
CK-MB.The colorwasmeasured by the absorbance under the
excitation of light at 450 nm. The concentration of CK-MB
was determined by comparing the absorbance of each sample
to the standard curve and expressed as ng/mL.
2.5. Endothelin-1 (ET-1). Measurement of ET-1 concentration
in the coronary effluent sampled at BS20 and 1 (Re-1) and 60
(Re-60)min of reperfusion was performed using a commer-
cially human ET-1 EIA kit 900-020 (Assay Designs, Inc., Ann
Arbor, MI) as described [31]. After collected effluent samples
were initially concentrated 4-fold by evaporation of KH
solution under a stream of dry nitrogen, they were assayed
in 96-well microplates according to enzyme immunoassays
for analysis of ET-1 concentration. Thereafter, the plates were
read at 450 nm and the concentration of ET-1 was expressed
as picograms ET-1 per milliliter effluent.
2.6. Free 15-F2t-Isoprostane (15-F2t-IsoP). 15-F2t-isoprostane
(15-F2t-IsoP), a specific marker of oxidative stress and lipid
peroxidation, is produced by oxidation of tissue phospho-
lipids and can be detected by using a commercial available
competitive enzyme immunoassay kit as described [32].
The effluent samples collected at BS20 and 1 (Re-1) and
60 (Re-60)min of reperfusion were assayed relying on
the competition between free 15-F2t-IsoP and 15-F2t-IsoP-
acetylcholinesterase conjugate (15-F2t-IsoP tracer) for a lim-
ited number of 15-F2t-IsoP specific rabbit antiserum binding
sites.The rabbit antiserum free 15-F2t-IsoP complex can bind
to the rabbit IgG mouse monoclonal antibody which was
previously attached to the well to develop an optimal yellow
color. The absorbance was measured spectrophotometrically
at a wavelength of 412 nm. The values of 15-F2t-IsoP were
expressed as pg/mL, respectively.
2.7. Protein Extraction and Western Immunoblotting. At the
end of reperfusion, LV tissues were removed and frozen for
Western blotting. The frozen LV tissues were lysed with lysis
buffer and centrifuged at 13,000 g for 30min.The supernatant
was collected as isolated total protein. The determination of
protein concentration was assayed as described [29]. Equal
amounts of protein were separated by 10–12% SDS PAGE
and transferred to polyvinylidene difluoride membranes for
1 hour.The membranes were blocked with 5% skimmed milk
for 2 hours and probedwith primary antibodies for CD36 and
GAPDH in trisbuffered saline containing 5% BSA followed
by incubation with anti-rabbit IgG conjugated to horseradish
peroxidase. Specific antigen-antibody complex was detected
by a standard enhanced chemiluminescence detection system
(GE Healthcare, Amersham, UK). The band densities were
quantified using Quantity One analysis software.
2.8. Statistical Analysis. Seven rats were needed in each group
to detect significant differences (𝑃 < 0.05) in animal studies
according to our previous and preliminary research. Cardiac
variables and chemical assay parameters were compared by
2-way ANOVA with repeated measures (GraphPad Prism,
USA). One-way ANOVA was used to test for differences in
infarct size between groups. Values are presented as mean ±
SEM. 𝑃 value less than 0.05 was considered statistically
significant different.
3. Results
3.1. Myocardial Infarct Size (IS) and CK-MB Release during
Ischemia Reperfusion. Infarct size (IS) as an index ofmyocar-
dial injury was expressed as a percentage of total area. The
postischemic IS was significantly reduced from 28 ± 5% in
the LG group to 22 ± 4% in the G group, 18 ± 5% in the G+P
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Figure 1: Effect of low glucose (LG) and glucose (G) on myocardial infarct size (IS) and CK-MB release during ischemia reperfusion. Rat
hearts were randomly assigned to be perfused with glucose concentration at LG, LG+propofol (LG+P), and LG+propofol+trimetazidine
(LG+P+TMZ) or with G, G+propofol (G+P), and G+propofol+trimetazidine (G+P+TMZ). Myocardial IS was measured by TTC staining.
Myocardial IS and cardiac CK-MB release were significantly higher in LG than in G (𝑃 < 0.05). Propofol significantly reduced IS and CK-MB
in G but not in LG. TMZ facilitated propofol induced IS and CK-MB reduction in LG but did not induce further propofol beneficial effects
on G. BS20, Re-1, and Re-60 are abbreviations of 20min after stabilization, 1 and 60min after reperfusion, respectively. Values are presented
as mean ± SEM.𝑁 = 7 per group. ∗𝑃 < 0.05 versus BS20; #𝑃 < 0.05 versus LG; +𝑃 < 0.05 versus LG+P; $𝑃 < 0.05 versus G.
group, and 16 ± 3% in the G+P+TMZ group (all 𝑃 < 0.05
versus LG, Figure 1(a)). Propofol treatment had no significant
impact upon IS in the LG+P group. However, TMZ used in
the LG+P+TMZ group restored the infarct sparing effect of
propofol (𝑃 < 0.05 versus LG and LG+P, Figure 1(a)).
As shown in Figure 1(b), effluent CK-MB release did not
significantly change during baseline. CK-MB release at Re-1
was significantly higher than its baseline corresponding value
(all 𝑃 < 0.05). However, at the end of 60min reperfusion,
CK-MB level was greater than its baseline value in the LG
group but did not significantly differ from baseline values in
other groups. Effluent CK-MB concentration in the LG+P
group decreased relative to the value in the LG group at
Re-1, but the decrease did not reach statistical significance
(𝑃 > 0.05). CK-MB concentrations in all normal glucose (G)
groups decreased more rapidly and were significantly lower
than that in the LG group (𝑃 < 0.05 versus LG). The FA
oxidation inhibitor TMZ preserved the effect of propofol in
reducing postischemic CK-MB release in the LG+P+TMZ
group (𝑃 < 0.05 versus LG and LG+P).
3.2. Contracture Development during Ischemia Reperfusion
and Functional Response to Ischemia Reperfusion. As shown
in Figure 2(a), at the end of 60min reperfusion, the mag-
nitude of LVEDP was significantly higher than that at BS20
in all groups (𝑃 < 0.05). The magnitude of LVEDP in the
G, G+P, and G+P+TMZ group was significantly lower than
that in the LG group at Re-60. However, LVEDP value in
the LG+P group did not significantly differ from that in the
LG group indicating that low glucose attenuated the ischemic
contracture reducing effect of propofol. TMZ treatment in
the LG+P+TMZ group augmented the effect of propofol
in reducing LVEDP value and led to a significant change
compared to the LG and LG+P group. TMZ treatment alone
tended to decrease LVEDP but did not reach significance on
this change in the G+P+TMZ group.
The LVDP did not change significantly over time during
baseline period and did not differ among groups. At Re-60,
the LVDP values were lower than that at BS20 in both the LG
and G groups as well as in LG+P groups (all 𝑃 < 0.05). At Re-
60, LVDP in the G group was significantly higher than that in
the LG group (𝑃 < 0.05), and propofol significantly further
increased LVDP in the G+P group (𝑃 < 0.05 versus G or LG,
Figure 2(b)). In addition, propofol tended to elevate LVDP in
the LG+P group, but the increase was not remarkable (𝑃 >
0.05 versus LG). LVDP function at Re-60 was significantly
enhanced by TMZ treatment in the G+P+TMZ group which
reached a level comparable to that at BS20.
3.3. Endothelin-1 (ET-1) Release and Coronary Perfusion
Pressure (CPP). Baseline effluent ET-1 concentrations had no
difference among groups. During reperfusion, ET-1 increased
significantly in all LG groups at RE-1 and Re-60 as compared
to baseline (𝑃 < 0.05 versus BS20, Figure 3(a)). Significant
increase in ET-1 did not occur in the normal glucose (G)
group until Re-60 and this increase in postischemic ET-1 was
prevented by propofol and the combination of propofol and
TMZ. Propofol plus TMZ but not propofol alone significantly
attenuated the increase in ET-1 during reperfusion at RE-1
and Re-60.
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Figure 2: Effect of low glucose (LG) and glucose (G) on left ventricular end-diastolic pressure (LVEDP) and left ventricle developed
pressure (LVDP) during ischemia reperfusion. LVEDP is not only a marker of diastolic function but also a good predictor of cardiac
mortality independent of LV ejection fraction. LVDP was calculated by subtracing LVEDP, from LV peak systolic pressure (LVSP). There
was significantly increase in LVEDP and decrease in LVDP in LG as compared to G (all 𝑃 < 0.05). Propofol significantly improved cardiac
function in G but not in LG. TMZ facilitated propofol cardioprotection in LG. Values are presented as mean ± SEM. 𝑁 = 7 per group.
∗
𝑃 < 0.05 versus BS20; #𝑃 < 0.05 versus LG; +𝑃 < 0.05 versus LG+P; $𝑃 < 0.05 versus G.
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Figure 3: Effect of low glucose (LG) and glucose (G) on endothelin-1 (ET-1) concentration and coronary perfusion pressure (CPP). ET-1
release and CPP were significantly increased in LG as compared to G (𝑃 < 0.05). Propofol significantly reduced cardiac ET-1 and CPP in
G but not in LG. TMZ facilitated propofol induced reduction in ET-1 and CPP in LG but did not in G. Re-10 is abbreviation of 10min after
reperfusion. Values are presented as mean ± SEM.𝑁 = 7 per group. ∗𝑃 < 0.05 versus BS20; #𝑃 < 0.05 versus LG; +𝑃 < 0.05 versus LG+P.
As shown in Figure 3(b), during reperfusion, CPP signif-
icantly increased upon reperfusion at Re-10 and at Re-60 in
the LG group and these significant increases in CPP were
attenuated by propofol plus TMZ but not propofol alone.
Neither propofol nor TMZ affected CPP at BS20. Significant
increase in CPP was not seen in the normal glucose group
until Re-60 (𝑃 < 0.05 versus BS20) and either propofol
alone or its combination with TMZ prevented the increase
in postischemic CPP.
3.4. 15-F2t-IsoPGeneration andCardiac CD36 Protein Expres-
sion during Ischemia Reperfusion. As shown in Figure 4,
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Figure 4: Effect of low glucose (LG) and glucose (G) on cardiac 15-F2t-isoprostane (15-F2t-IsoP) and cardiac CD36 protein expression.
Cardiac 15-F2t-IsoP, a specific index of ROS-induced oxidative stress, was higher in LG that was associated with higher cardiac lipid
transporter CD36 protein expression than in G. Propofol significantly reduced 15-F2t-IsoP as well as CD36 in G but not in LG. TMZ did
not change the protein level of CD36 in LG. BS20 is abbreviation of 20min after stabilization. Values are presented as mean ± SEM. 𝑁 = 7
per group. ∗𝑃 < 0.05 versus BS20; #𝑃 < 0.05 versus LG; +𝑃 < 0.05 versus LG+P.
effluent 15-F2t-IsoP release had no significant change among
each group at BS20. Free 15-F2t-IsoP content was dramat-
ically increased at Re-1 as compared to that at BS20 in all
groups (𝑃 < 0.05). Postischemic 15-F2t-IsoP levels in the
G group were lower than that in the LG group at Re-1
(𝑃 < 0.05). Propofol treatment did not have significant effect
on 15-F2t-IsoP content in the LG group (𝑃 > 0.1, LG+P
versus LG). Propofol in combination with TMZ remarkably
decreased the level of 15-F2t-IsoP in the LG+P+TMZ group
when compared to the LG+P group (𝑃 < 0.05). Propofol
treatment alone significantly reduced postischemic 15-F2t-
IsoP at Re-1 in the G group (𝑃 < 0.05, G+P versus G), while
propofol in combination with TMZ did not further decrease
the level of 15-F2t-IsoP (𝑃 > 0.1, G+P+TMZ versus G+P).
As shown in Figure 4(b), during reperfusion at Re-60,
cardiac CD36 protein expression was higher in the LG
group than in the G group; propofol plus TMZ but not
propofol alone reduced postischemic cardiac CD36 protein
expression in the LG group (𝑃 > 0.05, LG+P versus LG;
𝑃 < 0.05, LG+P+TMZ versus LG). In contrast, myocardial
protein expression of CD36 was downregulated in all glucose
(G) groups (all 𝑃 < 0.05 versus LG). Propofol treatment
moderately but not significantly decrease CD36 protein in the
G+P group. TMZ did not further suppress the expression of
CD36 in the G+P+TMZ group.
4. Discussion
We have shown in this study that postischemic myocardial
IS and cardiac CK-MB release were significantly greater
in low glucose group than in glucose group (𝑃 < 0.05),
which was associated with reduced LVDP and an increase
in postischemic cardiac contracture reflected as enhanced
LVEDP and increases in ET-1 release andCPP as compared to
glucose group (𝑃 < 0.05). Also postischemic cardiac 15-F2t-
isoprostane, a specific index of ROS-induced oxidative stress,
was higher in low glucose group that was associated with
higher cardiac lipid transporter CD36 protein expression
than that in glucose group. Propofol significantly reduced
IS and improved cardiac function and reduced cardiac ET-
1 and CPP as well as CD36 in glucose group but not in low
glucose group, indicating that enhancement of ROS induced
oxidative stress by low glucose plays a key role in compromis-
ing propofol cardioprotection. Further, both hemodynamic
and biochemical findings signaled a remarkably attenuated
myocardial injury and enhanced cardiac function recovery
by TMZ treatment in the LG+P+TMZ group as compared to
the LG group and the LG+P group. Together, these results for
the first time demonstrated that low glucose concentration as
seen during tight glycaemic control may not only promote
postischemic myocardial ROS formation through enhancing
FA oxidation and exacerbating myocardial IRI but also play a
critical role in unmasking propofol cardioprotection against
IRI.
15-F2t-IsoP, one of the most abundant F2t-isoprostanes,
was firstly reported by Morrow and colleagues in 1990 [33,
34], which is produced in vivo and has been intensively
used as a sensitive and reliable marker of oxidative stress
[33, 34]. Thus, measurement of 15-F2t-IsoP concentration
should potentially allow for exploration of the role of ROS
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in the pathophysiology of myocardial ischemic diseases. Our
previous study has demonstrated that 15-F2t-IsoP per se can
exacerbate myocardial IRI evidenced as elevated CK-MB
release, increased IS, and concomitant cardiac dysfunction
[31]. In the same study, 15-F2t-IsoP, applied before or present
in high concentration during ischemia, can lead to an
increase in effluent ET-1 concentration during reperfusion
in the isolated rat heart [31]. ET-1 has been known as one
of the most potent vasoconstrictors and postulated to be
attributable to the progression ofmyocardial IRI [35].We also
have found that 15-F2t-IsoP generation during myocardial
ischemia reperfusion in an isolated rat heart model can be
inhibited by treatment with 2,6-diisopropylphenol (propo-
fol), which led to improved postischemic cardiac functional
recovery [29]. Another study done by our group has also
determined that antioxidant therapy with Salvia miltiorrhiza
during cardiac surgery significantly reduces the lipid perox-
idation product malondialdehyde levels in the plasma with
concomitant reductions in ET-1 concentrations and improved
postoperative cardiac function in patients [36]. Despite these
findings of 15-F2t-IsoP in myocardial diseases, no evidence
exists to show propofol treatment effects on the alterations of
both 15-F2t-IsoP and ET-1 concentrations during myocardial
IRI under the context of different concentrations of glucose.
The current study extended previous study and observed a
significant reduction in ET-1 (Figure 3(a)) and 15-F2t-IsoP
(Figure 4(a)) concentration in propofol treatment groups
under glucose condition but not under low glucose condition.
It is plausible that antioxidant therapy with propofol may
have reduced ET-1 release during myocardial ischemia reper-
fusion through attenuating ROS induced oxidative stress
reflected as reduced 15-F2t-IsoP production under normal
glucose condition.However, under low glucose condition, the
potentially increased FAmetabolism subsequent to increased
CD36 expression may result in increased oxidative stress
which compromised propofol cardioprotection through its
antioxidant property. During reperfusion, the significant
increase in cardiac ET-1 release occurred early at 1min after
reperfusion (Figure 3(a)), which proceeded the changes in
CPP which did not significantly increase at Re-1min (data
not shown) until after 10min of reperfusion (Figure 3(b)).
This suggests that postischemic ET-1 release is, at least in part,
responsible for the increase in CPP.
The significant increases of 15-F2t-IsoP in all experimen-
tal groups at early reperfusion (1min) as compared to that
at baseline indicate increased oxidative stress during early
reperfusion. However, at the end of reperfusion (60min), 15-
F2t-IsoP concentration decreased to the same level as that at
baseline which was consistent with our previous study which
showed that 15-F2t-IsoP level was continuously increased
during ischemia and early reperfusion but decayed quickly
after about 30min during reperfusion in patients undergoing
coronary artery bypass grafting [37]. In contrast, ET-1 levels
remained elevated at least 24 hours after cardiopulmonary
bypass in patients [36]. The postischemic myocardial IS was
assessed 60min after reperfusionwith concomitantmeasures
of LV diastolic performance [38]. It should be noted that
although Langendorffmethod is an ideal experimentalmodel
utilized to assess cardiac function and metabolism ex vivo,
the measurement of right ventricular function which con-
tributed to overall cardiac function is not assessed that causes
some limitations in this study.
In this study, we detected that isolated rat hearts per-
fused with low glucose were more vulnerable to myocardial
injury. Low glucose exhibited a significant myocardial injury
evidenced by dramatically increased IS, CK-MB, and cardiac
dysfunction compared to glucose group and this was tightly
associated with increased 15-F2t-IsoP production and higher
cardiac CD36 protein expression. CD36 is a transmembrane
sarcolemmal protein considered as a major mediator of FA
transport and participated in enhancing cardiomyocyte FA
uptake and subsequently regulating FA oxidation rates in the
hearts.There is a growing body of evidence finding that CD36
overexpression can facilitate FA oxidation whereas CD36
ablation can lead to reduced FA uptake and FA oxidation
rates which is compensated by increased glucose oxidation
and consequently prevent IRI [39]. Our data found that
ROS production, reflected as 15-F2t-IsoP generation, was
significantly increased in rat heart with low glucose and
associated with increased CD36 expression indicating that
low glucose concentration at 5.5mMmay result in increased
FA oxidation and subsequently lead to lipid peroxidation
production and render the heart susceptible to myocardial
IRI. The fact that cardiac contractile dysfunction reflected as
increased LVEDP and decreased LVDP was accompanied by
increased CD36 level is in line with the viewpoint of Ussher
and Lopaschuk [40] which suggests that accelerated FA
oxidation can strongly affect perioperative cardiac function
recovery.The translocation of CD36 can be regulated by both
glucosemetabolism and cardiac contraction and the dramatic
reduction of CD36 after perfusion in propofol and TMZ
treated group may be due to rapid redistribution from the
functional lipid raft to nonfunctional nonraft membrane as
suggested [41], but further in depth mechanistic study in this
regard is merited.
Propofol has chemical structural similarity to that of the
phenol-based free radical scavenger vitamin E and possessed
antioxidant property [42]. Propofol at the concentrations 2–
4 𝜇g/mL failed to achieve cardioprotective effect on coronary
surgery patients [43]. However, propofol, when infused in
high doses, may potentially impair themetabolic functions of
blood vessels andmuscles of various organs and subsequently
lead to apparent heart failure, renal failure, andmetabolic aci-
dosis, which is known as propofol infusion syndrome [44]. In
our study, propofol applied at 5𝜇g/mL displayed a reduction
of contracture development evidenced by increased LVDP
function while decreased LVEDP confirmed that propofol
can improve postischemic myocardial functional recovery.
Our finding is in line with findings by others who showed
that propofol attenuated contracture development through
significantly facilitating energy metabolic recovery which
may provide tolerance to lethal cardiac IRI [45].
Another important finding of this study is the correlation
between different glucose concentrations and propofol car-
dioprotection against IRI. To our knowledge, this is the first
study to compare the cardioprotective effect of propofol on
isolated hearts perfused with low glucose (5.5mM) and nor-
mal glucose (8mM) concentration. Propofol under glucose
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8mM showed a robustmyocardial protection effect.Whereas
its cardioprotective effects vanished, the hearts were perfused
at low glucose at 5.5mM. Propofol had no significant effect on
ameliorating myocardial injury between the LG and LG+P
groups indicating that the abolishment of cardioprotective
effect with propofol may be a result of low glucose induced
enhancement of ROS production due to the increase of FA
oxidation which exceeded propofol’s antioxidant capacity.
Our finding differs from that of Wang et al. [41] as they
also showed that hearts exposed to propofol can increase
glucose oxidation and markedly decrease FA oxidation. This
discrepancymay be partially due to the fact that FA oxidation
increased by low glucose surpasses the decrease by propofol.
However, the exact mechanism is unclear and deserves
further study.
Our finding that low glucose concentration-mediated
cancellation of propofol cardioprotection can be restored by
the addition of the partial FA oxidation inhibitor TMZ with
concomitant reduction of postischemic oxidative stress pro-
vides indirect evidence that low concentration glucose may
induce increased FAoxidation and exacerbate oxidative stress
duringmyocardial IRI. Further, we showed that the protective
effect of TMZ on postischemic myocardial damage and
function recovery was more evident in low glucose group
than in normal glucose group.
Propofol has been studied extensively for its cardiopro-
tective effect [46]. However, that propofol treatment against
IRI by modulating FA oxidation using TMZ has not been
reported.The contribution of TMZ in propofol-mediated car-
diomyocytes protection is addressed for the first time by using
Langendorff perfused model. TMZ, a partial FA oxidation
inhibitor, is well established to have efficient effect against
ischemic damage as a result of increased glucose oxidation
through selectively suppressing key enzyme of FA oxidation
[47] and be regarded as an effective adjunctive treatment
against global ischemia reperfusion [48]. The present study
showed that TMZ supplementation restored isolated heart
with low glucose concentration sensitivity to propofol car-
dioprotection by decreases in myocardial IS and 15-F2t-IsoP
generation and enhancement in cardiac function which is
aligned with studies from Lopaschuk et al. [49] and Fragasso
et al. [50] as they also found that TMZ can improve functional
recovery and diminish injury to ischemic myocardium.
The novel finding that suppressing FA oxidation by TMZ
facilitated propofol cardioprotection under low glucose may
provide a potential direction on clinical therapies to combat
global myocardial ischemia.The findings of the current study
combined with our previous work on the cardioprotection
effect of propofol suggest that a combined strategy with
propofol and FA oxidation antagonism designed to specifi-
cally inhibit FA oxidation could pave theway for a therapeutic
approach for amelioration of cardiac injury.
The current experiment data presented herein supporting
the hypothesis that low glucose concentration induced the
formation of myocardial ROS through enhancing FA oxida-
tion may represent the major mechanism by which propofol
lost its cardioprotective effect against IRI. This may provide
a mechanism whereby the effectiveness of propofol cardio-
protection in patients is not consistent. Our study suggests
a novel therapy againstmyocardial IRI under low glucose that
single therapy could not achieve satisfied cardioprotection
but the combination use of propofol and TMZ can get better
recovery. The future work will have to be performed to fully
characterize the relationship of low glucose concentration
and propofol cardioprotection in the pathogenesis of IRI
and TMZ applied as anti-ischemic agent requires further
evaluation in the laboratory and clinical setting.
5. Conclusions
In summary, isolated rat hearts with low glucose concentra-
tion at 5.5mM lost sensitivity to propofol treatment through
enhancing FA oxidation and oxidative stress and TMZ sup-
plementation restored the sensitivity of isolated rat hearts to
propofol that was concomitant with diminished myocardial
IS, CK-MB release, ET-1, and 15-F2t-IsoP concentration as
well as improved cardiac function.
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